TSHA Short Volume
Taysha Gene Therapies, Inc. (TSHA) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $1.67B, listed on NASDAQ, employing roughly 73 people, carrying a beta of 1.23 to the broader market. Taysha Gene Therapies, Inc. Led by Sean Nolan, public since 2020-09-24.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-05-15
- Short Volume
- 471.2K
- Total Volume
- 1.2M
- Short %
- 38.98%
- 30-Day Avg Short %
- 57.75%
Showing 30 days of FINRA short volume data for Taysha Gene Therapies, Inc..
Learn how short volume is reported and how to read the data →
Frequently asked TSHA short volume questions
- What is the daily TSHA short volume?
- As of May 15, 2026, Taysha Gene Therapies, Inc. (TSHA) short volume is 471.2K shares against 1.2M total reported volume, or 38.98% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is TSHA short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does TSHA short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.